Meyka Pro banner
AbCellera Biologics Inc.

AbCellera Biologics Inc. Fundamental Analysis (NASDAQ: ABCL)

ABCL●NASDAQ
HealthcareBiotechnology
$9.69
$0.78(7.45%)
U.S. Market opens in 20h 8m

AbCellera Biologics Inc. Fundamental Analysis (NASDAQ: ABCL)

AbCellera Biologics Inc. (NASDAQ: ABCL) shows weak financial fundamentals with a PE ratio of -20.31, profit margin of -2.19%, and ROE of -15.35%. The company generates $0.1B in annual revenue with weak year-over-year growth of 1.61%.

Key Strengths

Cash Position24.78%
PEG Ratio-1.39
Current Ratio12.43

Areas of Concern

ROE-15.35%
Operating Margin-2.98%
We analyze ABCL's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -131.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-131.0/100

We analyze ABCL's fundamental strength across five key dimensions:

Efficiency Score

Weak

ABCL struggles to generate sufficient returns from assets.

ROA > 10%
-9.89%

Valuation Score

Excellent

ABCL trades at attractive valuation levels.

PE < 25
-20.31
PEG Ratio < 2
-1.39

Growth Score

Moderate

ABCL shows steady but slowing expansion.

Revenue Growth > 5%
1.61%
EPS Growth > 10%
10.91%

Financial Health Score

Excellent

ABCL maintains a strong and stable balance sheet.

Debt/Equity < 1
0.13
Current Ratio > 1
12.43

Profitability Score

Weak

ABCL struggles to sustain strong margins.

ROE > 15%
-1535.34%
Net Margin ≥ 15%
-2.19%
Positive Free Cash Flow
No

Key Financial Metrics

Is ABCL Expensive or Cheap?

P/E Ratio

ABCL trades at -20.31 times earnings. This suggests potential undervaluation.

-20.31

PEG Ratio

When adjusting for growth, ABCL's PEG of -1.39 indicates potential undervaluation.

-1.39

Price to Book

The market values AbCellera Biologics Inc. at 2.92 times its book value. This may indicate undervaluation.

2.92

EV/EBITDA

Enterprise value stands at -23.18 times EBITDA. This is generally considered low.

-23.18

How Well Does ABCL Make Money?

Net Profit Margin

For every $100 in sales, AbCellera Biologics Inc. keeps $-2.19 as profit after all expenses.

-2.19%

Operating Margin

Core operations generate -2.98 in profit for every $100 in revenue, before interest and taxes.

-2.98%

ROE

Management delivers $-15.35 in profit for every $100 of shareholder equity.

-15.35%

ROA

AbCellera Biologics Inc. generates $-9.89 in profit for every $100 in assets, demonstrating efficient asset deployment.

-9.89%

Following the Money - Real Cash Generation

Operating Cash Flow

AbCellera Biologics Inc. generates limited operating cash flow of $-77.24M, signaling weaker underlying cash strength.

$-77.24M

Free Cash Flow

AbCellera Biologics Inc. generates weak or negative free cash flow of $-95.13M, restricting financial flexibility.

$-95.13M

FCF Per Share

Each share generates $-0.29 in free cash annually.

$-0.29

FCF Yield

ABCL converts -2.92% of its market value into free cash.

-2.92%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-20.31

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.39

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.92

vs 25 benchmark

P/S Ratio

Price to sales ratio

46.93

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.13

vs 25 benchmark

Current Ratio

Current assets to current liabilities

12.43

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.15

vs 25 benchmark

ROA

Return on assets percentage

-0.10

vs 25 benchmark

ROCE

Return on capital employed

-0.14

vs 25 benchmark

How ABCL Stacks Against Its Sector Peers

MetricABCL ValueSector AveragePerformance
P/E Ratio-20.3130.24 Better (Cheaper)
ROE-15.35%540.00% Weak
Net Margin-218.54%-2322.00% (disorted) Weak
Debt/Equity0.130.08 Weak (High Leverage)
Current Ratio12.435.59 Strong Liquidity
ROA-9.89%-17516.00% (disorted) Weak

ABCL outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews AbCellera Biologics Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-71.62%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-208.46%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-609.73%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ